ArticleNPJ breast cancer2019
Homologous recombination DNA repair defects in
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in NPJ breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 57 citations in OpenAlex.
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Breast-Ovarian Hereditary Cancer Syndrome: BeyondCurrent oncology (Toronto, Ont.) · 2026Review
- Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.Nature · 2026Article
- Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas.International journal of molecular sciences · 2025Article
- Review
- Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing.NPJ genomic medicine · 2025Article
- Hodgkin lymphoma and Ewing sarcoma in pediatric patient carrying germlineFrontiers in oncology · 2025Article
- The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.Genome medicine · 2024Article
- PALB2-mutated human mammary cells display a broad spectrum of morphological and functional abnormalities induced by increased TGFβ signaling.Cellular and molecular life sciences : CMLS · 2024Article
- Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors.Nature communications · 2024Article
- Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients.PloS one · 2024Article
- Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer.Frontiers in immunology · 2024Article
- Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond.DNA repair · 2023Review
- The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.Diagnostics (Basel, Switzerland) · 2023Article
- DNA repair pathways in breast cancer: from mechanisms to clinical applications.Breast cancer research and treatment · 2023Review
- SIRT1 regulates DNA damage signaling through the PP4 phosphatase complex.Nucleic acids research · 2023Article
- Review
- Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants.Journal of the National Cancer Institute · 2023Article
- Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision Oncology.Cancers · 2022Review
- Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.Oncogene · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
39 authors at 20 institutions in 13 countries.
Anqi Li *1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.ORCID 0000-0003-1409-1858
Felipe C Geyer *1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Pedro Blecua3Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Ju Youn Lee1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Pier Selenica1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
David N Brown1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Fresia Pareja1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Simon S K Lee1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Rahul Kumar1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.ORCID 0000-0002-6927-5390
Barbara Rivera4Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec Canada.ORCID 0000-0001-9434-6288
Rui Bi1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Salvatore Piscuoglio1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.ORCID 0000-0003-2686-2939
Hannah Y Wen1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
John R Lozada1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.ORCID 0000-0001-8953-4110
Rodrigo Gularte-Mérida1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.ORCID 0000-0002-4383-2523
Luca Cavallone4Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec Canada.
kConFab Investigators
Zoulikha Rezoug7Cancer Prevention Center, Jewish General Hospital, Montreal, Quebec Canada.
Tu Nguyen-Dumont8Genetic Epidemiology Laboratory, Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia.
Paolo PeterlongoIFOM, The Italian Foundation for Cancer Research Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0001-6951-6855
Carlo Tondini11Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Thorkild Terkelsen12Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
Karina Rønlund13Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark.
Susanne E Boonen14Clinical Genetics Unit, Department of Pediatrics, Zealand University Hospital, Roskilde, Denmark.
Arto Mannerma15Biocenter Kuopio and Cancer Center of Easter Finland, University of Eastern Finland, Kuopio, Finland.
Robert Winqvist16Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
Marketa Janatova17Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Pathmanathan Rajadurai18Department of Pathology, Subang Jaya Medical Centre, Subang Jaya, Selangor Malaysia.
Bing Xia19Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ USA.
Larry Norton20Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Mark E Robson20Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA.ORCID 0000-0002-3109-1692
Pei-Sze NgCancer Research Malaysia, Subang Jaya, Malaysia.
Lai-Meng Looi22Department of Pathology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0001-8325-0117
Melissa C Southey8Genetic Epidemiology Laboratory, Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia.
Britta Weigelt1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Teo Soo-HwangCancer Research Malaysia, Subang Jaya, Malaysia.
Marc Tischkowitz24Department of Medical Genetics, University of Cambridge, Cambridge, UK.
William D Foulkes5Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec Canada.ORCID 0000-0001-7427-4651
Jorge S Reis-Filho1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Memorial Sloan Kettering Cancer Center · USThe Royal Melbourne Hospital · AUPeter MacCallum Cancer Centre · AUThe University of Queensland · AUQIMR Berghofer Medical Research Institute · AURoyal Children's Hospital · AUThe University of Melbourne · AUGarvan Institute of Medical Research · AURoyal Adelaide Hospital · AURoyal North Shore Hospital · AUJewish General Hospital · CAThe University of Sydney · AUAuckland City Hospital · NZAustralian National University · AUCancer Council Victoria · AUKing Edward Memorial Hospital · AUSouth Australia Pathology · AUSt John of God Subiaco Hospital · AUUniversity of Malaya · MYWollongong Hospital · AU
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MRole of PALB2 in the DNA Damage Response and Cancer SuppressionR01CA138804 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI XIA, BING · 2009 to 2024
$5.5MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA138804
Abstract
Mono-allelic germline pathogenic variants in the
Indexed as
Breast cancerCancer geneticsCancer genomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.